GSK2838232 |
| Katalog-Nr.GC12329 |
GSK2838232 hemmt die HIV-Reverse-Transkriptase-AktivitÄt Über ein breites Spektrum von HIV-1-Isolaten, extrahiert aus Patent WO/2013090664A1, Verbindung 51.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1443461-21-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GSK2838232 is an HIV-1 maturation inhibitor [1] [2].
HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. Maturation inhibitors bind the gag protein, which leads to the formation of immature, noninfectious virus particles incapable of infecting other cells. Also, maturation inhibitors inhibit HIV infections with resistance.
GSK2838232 is a HIV-1 maturation inhibitor and is active against a broad range of isolates, including those resistant to bevirimat [1]. GSK2838232 was developed for the treatment of chronic HIV infection. A phase I study in HIV-negative individuals had been completed. Single doses of 5, 10 or 20 mg GSK2838232 were used to evaluate the initial safety, tolerability, pharmacokinetics profile, and the effects of food and ritonavir on GSK2838232’s bioavailability and pharmacokinetics [2].
References:
[1]. Olender SA, Taylor BS, Wong M, et al. CROI 2015: Advances in Antiretroviral Therapy. CROI 2015 Highlights: Antiretroviral Therapy Volume 23 Issue 1 March/April 2015.
[2]. Horn T, Collins S. The Antiretroviral Pipeline. Antiretrovirals, 2014 PIPELINE REPORT.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *